Shanghai Key Laboratory of Molecular Imaging, 74753Jiading District Central Hospital Affiliated Shanghai University of Medicine and Health Sciences, Shanghai, China.
Department of Imaging & Pathology, 71510Biomedical Sciences Group, KU Leuven, Leuven, Flanders, Belgium.
Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221136716. doi: 10.1177/15330338221136716.
Radical treatment of malignant solid tumors should aim to be less traumatic, precise, and effective. OncoCiDia, as a noninvasive, sequential dual-targeting, small-molecule, broad spectrum anticancer theranostic approach, may fulfill these requirements of solid cancer (Onco) treatment with both tumoricidal (Ci) and diagnostic (Dia) effects. However, it is unlikely to cure patients with cancer, especially those with large and irregular tumors and with tumors residing in certain organs, such as the brain and pancreas, because of insufficient necrosis generation. To amplify ablative efficacy, this shortcoming could be overcome by combining high-intensity focused ultrasound (HIFU) with the use of a vascular-disrupting agent (VDA) and a radioactively labeled necrosis avid compound (NAC), such as I-Hypericin (I-Hyp), which are the first and second targeting drugs used in OncoCiDia. This study proposes the combined use of OncoCiDia and HIFU (Onco-HIFU-CiDia) as a synergistic treatment for malignant tumors to achieve a curative multimodality and multidrug regimen for patients with solid cancers, in accordance with the current trend of cancer patient care.
恶性实体瘤的根治性治疗应尽量减少创伤、精准和有效。OncoCiDia 作为一种非侵入性、序贯双靶向、小分子、广谱抗癌治疗方法，可能具有杀伤肿瘤（Ci）和诊断（Dia）的双重作用，满足实体瘤（Onco）治疗的这些要求。然而，由于坏死生成不足，它不太可能治愈癌症患者，尤其是那些肿瘤较大且不规则、位于某些器官（如脑和胰腺）的患者。为了增强消融效果，可以通过将高强度聚焦超声（HIFU）与血管破坏剂（VDA）和放射性标记的坏死靶向化合物（NAC）（如 I-Hypericin，I-Hyp）联合使用来克服这一缺陷，这两种药物是 OncoCiDia 中使用的第一和第二种靶向药物。本研究提出将 OncoCiDia 和 HIFU 联合使用（Onco-HIFU-CiDia）作为恶性肿瘤的协同治疗方法，为实体瘤患者提供一种治愈性的多模式和多药物治疗方案，以满足当前癌症患者治疗的趋势。
